Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Silo Pharma Q3 2026 Results: Net Loss of $359K, Loss Narrows

For the nine months ended September 30, 2026, Silo Pharma reported a net loss of $2.84 million, an improvement from the $3.35 million loss in the prior year period. The company's cash position increased to $6.09 million, bolstered by a $0.70 million gain from the termination of a sublicense agreement and financing activities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue—0.0
Profit before tax-0.4-1.1
Net income-0.4-1.1
EPS (diluted, $ a share)$-0.21$-1.79

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: SILO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Silo Pharma, Inc.: key numbers

Share price
$1.58Close, Nov 16
Market cap
$3.4M
Shares outstanding
2.16MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Silo Pharma, Inc.

All →
5:08 PM ET 8-K
Capital Raise

Silo Pharma Capital Raise of $850K

Silo Pharma entered into securities purchase agreements with accredited investors for a private placement of 136,005 common shares and 430,661 pre-funded warrants. The offering is expected to generate approximately $815,000 in net proceeds for working capital and general corporate purposes. The company also agreed to file a registration statement for the resale of the securities within 30 days of the agreement.

Value
$850K
4:30 PM ET 8-K
M&A Deal

Silo Pharma M&A Deal with Larry King

Silo Pharma, Inc. entered into an asset purchase agreement with Larry King to acquire certain software and related intellectual property. In consideration for the assets, the company issued 150,000 shares of its common stock, which are subject to a 12-month lock-up period.

Counterparty
Larry King
4:37 PM ET 8-K
M&A Deal

Silo Pharma M&A Deal with Norsight Consulting Inc.

Silo Pharma, Inc. entered into an asset purchase agreement to acquire software, technology, and related intellectual property from Norsight Consulting Inc. In consideration for the assets, Silo Pharma issued a warrant to Norsight to purchase up to 300,000 shares of common stock at an exercise price of $1.51 per share. The acquired assets include trademarks, domain names, data, and trade secrets related to the purchased technology.

Counterparty
Norsight Consulting Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.